Plato Investment Management Adds $5.90 Million Stake in AstraZeneca
Plato Investment Management disclosed a new AstraZeneca holding of 31,725 shares worth about $5.90M, while Lebenthal Global Advisors reported a new position worth about $1.22M. Penobscot Investment Management also increased its stake, and several firms reiterated buy ratings. AstraZeneca reported $2.63 EPS and 6.4% revenue growth, topping consensus.